Baidu
map

JCEM:成人隐匿性自身免疫糖尿病患者血清硬化蛋白和骨转换

2018-03-03 MedSci MedSci原创

大家都知道在1型和2型糖尿病(T2D)中骨形成受损,而骨形成的拮抗剂硬骨素仅在T2D中增加。目前没有关于成人隐匿性自身免疫性糖尿病(LADA)的数据,LADA是一种自身免疫型糖尿病,诊断时可能在临床上与T2D相似。

大家都知道在1型和2型糖尿病(T2D)中骨形成受损,而骨形成的拮抗剂硬骨素仅在T2D中增加。目前没有关于成人隐匿性自身免疫糖尿病(LADA)的数据,LADA是一种自身免疫糖尿病诊断时可能在临床上与T2D相似。

近日在JCEM上发表的一篇文章评估了LADA与T2D相比血清硬化蛋白和骨转换标志物,以及硬化蛋白是否受T2D或LADA代谢综合征(MetS)的影响。该横断面研究包括来自Action LADA和NIRAD队列的98例T2D和89例LADA患者。根据MetS状态进一步划分患者。非糖尿病受试者(n = 53)用作对照。分析血清硬化蛋白,骨形成(P1NP)和骨吸收(CTX)。

研究结果表明即使分析仅限于MetS受试者(调整后的p = 0.03),T2D受试者的硬化素水平也高于LADA(p = 0.0008,调整了性别和BMI)。分别对T2D和LADA进行分析,结果发现硬化蛋白在有和无MetS受试者之间存在相似性,但在T2D中,硬化蛋白与MetS特征数呈正相关(P趋势= 0.001),而LADA则无此趋势。具有T2D或LADA的受试者具有比对照低的CTX(p = 0.0003),并且P1NP没有显着降低。硬化蛋白与年龄或HbA1c无关,但与BMI(ρ= 0.29; p = 0.0001),HDL(ρ= -0.23; p = 0.003),甘油三酯(ρ= 0.19; p = 0.002)和自诊断以来的时间(ρ = 0.32,p <0.0001)有关。

上述研究寄过表明与对照相比,LADA患者的骨吸收较低,类似于T2D。在T2D中硬化蛋白增加但在LADA中不增加,表明仅在T2D中可能对骨代谢起作用。

原始出处:

Nicola Napol.et al. Serum sclerostin and bone turnover in latent autoimmune diabetes in adults. J Clin Endocrinol Metab. 2018.

本文系梅斯医学(MedSci)原创编译整理,转载需授权!


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1777784, encodeId=1f841e7778472, content=<a href='/topic/show?id=eb9610265ed' target=_blank style='color:#2F92EE;'>#JCEM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10265, encryptionId=eb9610265ed, topicName=JCEM)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2a4439169927, createdName=smallant2015, createdTime=Thu Nov 22 12:16:00 CST 2018, time=2018-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2063166, encodeId=61a920631666a, content=<a href='/topic/show?id=14fb10264d7' target=_blank style='color:#2F92EE;'>#JCE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10264, encryptionId=14fb10264d7, topicName=JCE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e656479, createdName=achengzhao, createdTime=Fri Sep 14 20:16:00 CST 2018, time=2018-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1936092, encodeId=52af1936092d2, content=<a href='/topic/show?id=1908984822d' target=_blank style='color:#2F92EE;'>#隐匿性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98482, encryptionId=1908984822d, topicName=隐匿性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b71f2500114, createdName=1179102698_36768926, createdTime=Tue Apr 03 12:16:00 CST 2018, time=2018-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1474451, encodeId=6d4f14e445105, content=<a href='/topic/show?id=935fe6718e3' target=_blank style='color:#2F92EE;'>#糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76718, encryptionId=935fe6718e3, topicName=糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Mon Mar 05 02:16:00 CST 2018, time=2018-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1618448, encodeId=ed8f161844877, content=<a href='/topic/show?id=5dbc98480ef' target=_blank style='color:#2F92EE;'>#隐匿#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98480, encryptionId=5dbc98480ef, topicName=隐匿)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1caf19894563, createdName=41514493@qq.com, createdTime=Mon Mar 05 02:16:00 CST 2018, time=2018-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=292602, encodeId=d8ef292602e2, content=学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Sat Mar 03 11:21:52 CST 2018, time=2018-03-03, status=1, ipAttribution=)]
    2018-11-22 smallant2015
  2. [GetPortalCommentsPageByObjectIdResponse(id=1777784, encodeId=1f841e7778472, content=<a href='/topic/show?id=eb9610265ed' target=_blank style='color:#2F92EE;'>#JCEM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10265, encryptionId=eb9610265ed, topicName=JCEM)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2a4439169927, createdName=smallant2015, createdTime=Thu Nov 22 12:16:00 CST 2018, time=2018-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2063166, encodeId=61a920631666a, content=<a href='/topic/show?id=14fb10264d7' target=_blank style='color:#2F92EE;'>#JCE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10264, encryptionId=14fb10264d7, topicName=JCE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e656479, createdName=achengzhao, createdTime=Fri Sep 14 20:16:00 CST 2018, time=2018-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1936092, encodeId=52af1936092d2, content=<a href='/topic/show?id=1908984822d' target=_blank style='color:#2F92EE;'>#隐匿性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98482, encryptionId=1908984822d, topicName=隐匿性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b71f2500114, createdName=1179102698_36768926, createdTime=Tue Apr 03 12:16:00 CST 2018, time=2018-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1474451, encodeId=6d4f14e445105, content=<a href='/topic/show?id=935fe6718e3' target=_blank style='color:#2F92EE;'>#糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76718, encryptionId=935fe6718e3, topicName=糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Mon Mar 05 02:16:00 CST 2018, time=2018-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1618448, encodeId=ed8f161844877, content=<a href='/topic/show?id=5dbc98480ef' target=_blank style='color:#2F92EE;'>#隐匿#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98480, encryptionId=5dbc98480ef, topicName=隐匿)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1caf19894563, createdName=41514493@qq.com, createdTime=Mon Mar 05 02:16:00 CST 2018, time=2018-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=292602, encodeId=d8ef292602e2, content=学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Sat Mar 03 11:21:52 CST 2018, time=2018-03-03, status=1, ipAttribution=)]
    2018-09-14 achengzhao
  3. [GetPortalCommentsPageByObjectIdResponse(id=1777784, encodeId=1f841e7778472, content=<a href='/topic/show?id=eb9610265ed' target=_blank style='color:#2F92EE;'>#JCEM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10265, encryptionId=eb9610265ed, topicName=JCEM)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2a4439169927, createdName=smallant2015, createdTime=Thu Nov 22 12:16:00 CST 2018, time=2018-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2063166, encodeId=61a920631666a, content=<a href='/topic/show?id=14fb10264d7' target=_blank style='color:#2F92EE;'>#JCE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10264, encryptionId=14fb10264d7, topicName=JCE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e656479, createdName=achengzhao, createdTime=Fri Sep 14 20:16:00 CST 2018, time=2018-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1936092, encodeId=52af1936092d2, content=<a href='/topic/show?id=1908984822d' target=_blank style='color:#2F92EE;'>#隐匿性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98482, encryptionId=1908984822d, topicName=隐匿性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b71f2500114, createdName=1179102698_36768926, createdTime=Tue Apr 03 12:16:00 CST 2018, time=2018-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1474451, encodeId=6d4f14e445105, content=<a href='/topic/show?id=935fe6718e3' target=_blank style='color:#2F92EE;'>#糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76718, encryptionId=935fe6718e3, topicName=糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Mon Mar 05 02:16:00 CST 2018, time=2018-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1618448, encodeId=ed8f161844877, content=<a href='/topic/show?id=5dbc98480ef' target=_blank style='color:#2F92EE;'>#隐匿#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98480, encryptionId=5dbc98480ef, topicName=隐匿)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1caf19894563, createdName=41514493@qq.com, createdTime=Mon Mar 05 02:16:00 CST 2018, time=2018-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=292602, encodeId=d8ef292602e2, content=学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Sat Mar 03 11:21:52 CST 2018, time=2018-03-03, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1777784, encodeId=1f841e7778472, content=<a href='/topic/show?id=eb9610265ed' target=_blank style='color:#2F92EE;'>#JCEM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10265, encryptionId=eb9610265ed, topicName=JCEM)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2a4439169927, createdName=smallant2015, createdTime=Thu Nov 22 12:16:00 CST 2018, time=2018-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2063166, encodeId=61a920631666a, content=<a href='/topic/show?id=14fb10264d7' target=_blank style='color:#2F92EE;'>#JCE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10264, encryptionId=14fb10264d7, topicName=JCE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e656479, createdName=achengzhao, createdTime=Fri Sep 14 20:16:00 CST 2018, time=2018-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1936092, encodeId=52af1936092d2, content=<a href='/topic/show?id=1908984822d' target=_blank style='color:#2F92EE;'>#隐匿性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98482, encryptionId=1908984822d, topicName=隐匿性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b71f2500114, createdName=1179102698_36768926, createdTime=Tue Apr 03 12:16:00 CST 2018, time=2018-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1474451, encodeId=6d4f14e445105, content=<a href='/topic/show?id=935fe6718e3' target=_blank style='color:#2F92EE;'>#糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76718, encryptionId=935fe6718e3, topicName=糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Mon Mar 05 02:16:00 CST 2018, time=2018-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1618448, encodeId=ed8f161844877, content=<a href='/topic/show?id=5dbc98480ef' target=_blank style='color:#2F92EE;'>#隐匿#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98480, encryptionId=5dbc98480ef, topicName=隐匿)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1caf19894563, createdName=41514493@qq.com, createdTime=Mon Mar 05 02:16:00 CST 2018, time=2018-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=292602, encodeId=d8ef292602e2, content=学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Sat Mar 03 11:21:52 CST 2018, time=2018-03-03, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1777784, encodeId=1f841e7778472, content=<a href='/topic/show?id=eb9610265ed' target=_blank style='color:#2F92EE;'>#JCEM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10265, encryptionId=eb9610265ed, topicName=JCEM)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2a4439169927, createdName=smallant2015, createdTime=Thu Nov 22 12:16:00 CST 2018, time=2018-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2063166, encodeId=61a920631666a, content=<a href='/topic/show?id=14fb10264d7' target=_blank style='color:#2F92EE;'>#JCE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10264, encryptionId=14fb10264d7, topicName=JCE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e656479, createdName=achengzhao, createdTime=Fri Sep 14 20:16:00 CST 2018, time=2018-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1936092, encodeId=52af1936092d2, content=<a href='/topic/show?id=1908984822d' target=_blank style='color:#2F92EE;'>#隐匿性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98482, encryptionId=1908984822d, topicName=隐匿性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b71f2500114, createdName=1179102698_36768926, createdTime=Tue Apr 03 12:16:00 CST 2018, time=2018-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1474451, encodeId=6d4f14e445105, content=<a href='/topic/show?id=935fe6718e3' target=_blank style='color:#2F92EE;'>#糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76718, encryptionId=935fe6718e3, topicName=糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Mon Mar 05 02:16:00 CST 2018, time=2018-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1618448, encodeId=ed8f161844877, content=<a href='/topic/show?id=5dbc98480ef' target=_blank style='color:#2F92EE;'>#隐匿#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98480, encryptionId=5dbc98480ef, topicName=隐匿)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1caf19894563, createdName=41514493@qq.com, createdTime=Mon Mar 05 02:16:00 CST 2018, time=2018-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=292602, encodeId=d8ef292602e2, content=学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Sat Mar 03 11:21:52 CST 2018, time=2018-03-03, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1777784, encodeId=1f841e7778472, content=<a href='/topic/show?id=eb9610265ed' target=_blank style='color:#2F92EE;'>#JCEM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10265, encryptionId=eb9610265ed, topicName=JCEM)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2a4439169927, createdName=smallant2015, createdTime=Thu Nov 22 12:16:00 CST 2018, time=2018-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2063166, encodeId=61a920631666a, content=<a href='/topic/show?id=14fb10264d7' target=_blank style='color:#2F92EE;'>#JCE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10264, encryptionId=14fb10264d7, topicName=JCE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e656479, createdName=achengzhao, createdTime=Fri Sep 14 20:16:00 CST 2018, time=2018-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1936092, encodeId=52af1936092d2, content=<a href='/topic/show?id=1908984822d' target=_blank style='color:#2F92EE;'>#隐匿性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98482, encryptionId=1908984822d, topicName=隐匿性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b71f2500114, createdName=1179102698_36768926, createdTime=Tue Apr 03 12:16:00 CST 2018, time=2018-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1474451, encodeId=6d4f14e445105, content=<a href='/topic/show?id=935fe6718e3' target=_blank style='color:#2F92EE;'>#糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76718, encryptionId=935fe6718e3, topicName=糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Mon Mar 05 02:16:00 CST 2018, time=2018-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1618448, encodeId=ed8f161844877, content=<a href='/topic/show?id=5dbc98480ef' target=_blank style='color:#2F92EE;'>#隐匿#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98480, encryptionId=5dbc98480ef, topicName=隐匿)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1caf19894563, createdName=41514493@qq.com, createdTime=Mon Mar 05 02:16:00 CST 2018, time=2018-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=292602, encodeId=d8ef292602e2, content=学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Sat Mar 03 11:21:52 CST 2018, time=2018-03-03, status=1, ipAttribution=)]
    2018-03-03 1ddf0692m34(暂无匿称)

    学习了.谢谢分享

    0

相关资讯

解读LADA China研究——中国成人自身免疫糖尿病的首项全国性多中心研究

【导语】LADA China 研究是在中国新诊断2 型糖尿病患者中首次开展的一项全国多中心调查。该项研究的最新研究成果已在Diabetes 杂志(2013)发表。本文介绍LADA China研究的主要成果,并进一步讨论其重要的临床意义。(作者:中南大学湘雅二医院内分泌科 向宇飞 周智广)糖尿病在中国乃至世界范围快速增长。其中有一类由T淋巴细胞介导的胰岛β细胞逐渐破坏的自身免疫糖尿病,既往多在儿童青

Baidu
map
Baidu
map
Baidu
map